Our analysts just identified a stock with the potential to be the next Nvidia. Management is executing a planned leadership transition, elevating Ryan Cohlhepp to CEO to leverage his commercial oncology experience as the company nears potential launch. Three-year follow-up data presented at ASCO 2026 demonstrated that TGF-beta inhibition nearly doubled overall survival versus standard of care pembrolizumab in the pivotal dose cohort. Management attributes clinical success to the mechanistic foundation of TGF-beta inhibition, which drives deeper tumor penetration and immune cell infiltration compared to standard EGFR-directed therapies. Operational expansion is underway with over 200 active clinical sites and the initiation of the FORTIFI-FLEX study to optimize dosing regimens for future market adoption.